1134 related articles for article (PubMed ID: 21691074)
21. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
22. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells.
Song P; Hai Y; Wang X; Zhao L; Chen B; Cui P; Xie Q; Yu L; Li Y; Wu Z; Li H
Arch Pharm Res; 2018 Apr; 41(4):467-480. PubMed ID: 29542005
[TBL] [Abstract][Full Text] [Related]
23. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
24. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
26. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
Cho HD; Lee KW; Won YS; Kim JH; Seo KI
J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
[TBL] [Abstract][Full Text] [Related]
27. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
[TBL] [Abstract][Full Text] [Related]
28. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
29. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.
Awazu Y; Mizutani A; Nagase Y; Tsuchiya S; Nakamura K; Kakoi Y; Kitahara O; Takeuchi T; Yamasaki S; Miyamoto N; Iwata H; Miki H; Imamura S; Hori A
Cancer Sci; 2013 Apr; 104(4):486-94. PubMed ID: 23305239
[TBL] [Abstract][Full Text] [Related]
30. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
31. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
32. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
[TBL] [Abstract][Full Text] [Related]
33. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.
Kamiyama H; Kakeya H; Usui T; Nishikawa K; Shoji M; Hayashi Y; Osada H
Oncol Res; 2008; 17(1):11-21. PubMed ID: 18488711
[TBL] [Abstract][Full Text] [Related]
34. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation.
Kwak HJ; Park MJ; Park CM; Moon SI; Yoo DH; Lee HC; Lee SH; Kim MS; Lee HW; Shin WS; Park IC; Rhee CH; Hong SI
Int J Cancer; 2006 Jun; 118(11):2711-20. PubMed ID: 16388516
[TBL] [Abstract][Full Text] [Related]
35. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
[TBL] [Abstract][Full Text] [Related]
36. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
Saraswati S; Kumar S; Alhaider AA
Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
[TBL] [Abstract][Full Text] [Related]
37. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
38. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
39. An-te-xiao capsule inhibits tumor growth in non-small cell lung cancer by targeting angiogenesis.
Han L; Wang JN; Cao XQ; Sun CX; Du X
Biomed Pharmacother; 2018 Dec; 108():941-951. PubMed ID: 30372906
[TBL] [Abstract][Full Text] [Related]
40. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]